Compounding Pharmacy Regulatory Landscape Tightens as FDA and Congress Act on GLP-1 Enforcement

A Year of Regulatory Reckoning

The compounding pharmacy industry is navigating its most significant regulatory shift since the Drug Quality and Security Act of 2013. Throughout 2025 and into 2026, a combination of FDA enforcement actions, proposed federal legislation, and state-level regulatory changes has fundamentally altered the operating environment for both 503A traditional pharmacies and 503B outsourcing facilities.

At the center of the upheaval is the GLP-1 receptor agonist class. After resolving the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, the FDA established phased enforcement deadlines for compounders to wind down operations. As of mid-2025, compounding of essentially a copy of either agent was no longer legally permissible for 503A or 503B entities, ending a period during which compounding pharmacies had supplied millions of patients with lower-cost alternatives to brand-name Ozempic, Wegovy, Mounjaro, and Zepbound.

The SAFE Drugs Act

On December 9, 2025, Representatives Rudy Yakym and Andre Carson introduced House of Representatives Bill 6509, the Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025. The legislation represents the most comprehensive proposed overhaul of compounding law in over a decade.

For 503A pharmacies, the Act would codify the definition of "essentially a copy of a commercially available drug product" and impose a hard cap of 20 units per month for any drug meeting that definition, unless the compound is tailored to an individual patient's specific clinical need. For 503B outsourcing facilities, the Act would require a pre-compounding inspection before a facility initiates work on a new drug and mandate biennial re-inspections for facilities compounding more than 100 products annually.

The bill also targets telehealth prescribing practices that emerged during the pandemic, proposing new oversight requirements for providers who prescribe compounded medications through virtual consultations.

FDA Bulk Drug Substance Policy

Effective January 7, 2025, the FDA finalized its interim policy on compounding with bulk drug substances, closing a significant pathway that compounders had used to produce medications. Under the new framework, pharmacies may no longer compound with newly proposed bulk drug substances unless and until the FDA completes its review process and includes the substance on its final approved list. This change affects both 503A pharmacies operating under the traditional pharmacy exemption and 503B outsourcing facilities.

The FDA has also clarified that its enforcement priorities will focus on facilities that continue to compound copies of commercially available drugs after shortage resolutions, those that distribute compounded products without valid patient-specific prescriptions, and facilities that fail to meet current good manufacturing practice requirements.

State-Level Activity

Several states have introduced or implemented measures in late 2025 and early 2026 that narrow the circumstances under which compounded drugs may be prepared or distributed. These state-level actions expand documentation and recordkeeping obligations and, in some cases, extend pharmacy board oversight to clinical settings that administer compounded drugs. The trend reflects growing concern among state regulators about quality control and patient safety in the compounding sector.

Industry Response

Compounding industry trade groups have pushed back, arguing that the proposed restrictions would reduce patient access to customized medications and harm patients who cannot tolerate commercially available formulations. The Alliance for Pharmacy Compounding and other organizations have lobbied for amendments that would preserve compounding access while addressing legitimate safety concerns.

For practitioners and patients who rely on compounded medications, the regulatory landscape demands careful attention. The days of readily available compounded GLP-1 agonists appear to be over, and the broader compounding sector faces a more restrictive operating environment for the foreseeable future.